Disc Medicine (NASDAQ:IRON – Get Free Report) and eXoZymes (NASDAQ:EXOZ – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.
Risk & Volatility
Disc Medicine has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, eXoZymes has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500.
Earnings & Valuation
This table compares Disc Medicine and eXoZymes”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Disc Medicine | N/A | N/A | -$109.36 million | ($5.35) | -14.90 |
| eXoZymes | $70,000.00 | 1,261.20 | -$5.86 million | ($0.77) | -13.65 |
eXoZymes has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Disc Medicine and eXoZymes’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Disc Medicine | N/A | -31.61% | -28.96% |
| eXoZymes | N/A | -104.58% | -79.55% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Disc Medicine and eXoZymes, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Disc Medicine | 1 | 1 | 11 | 0 | 2.77 |
| eXoZymes | 1 | 0 | 0 | 0 | 1.00 |
Disc Medicine presently has a consensus target price of $119.45, suggesting a potential upside of 49.84%. Given Disc Medicine’s stronger consensus rating and higher possible upside, analysts plainly believe Disc Medicine is more favorable than eXoZymes.
Insider and Institutional Ownership
83.7% of Disc Medicine shares are owned by institutional investors. 3.6% of Disc Medicine shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
About Disc Medicine
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company’s preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
About eXoZymes
eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
